LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced that it has reached commercial terms with two leading pharmacy retail operators in Caracas, Venezuela, to support the planned deployment of its AI-powered prescription processing and pharmaceutical fulfillment platform. The initiative is expected to underpin the company's broader Latin American commercialization strategy and establish an operational framework for its expanding healthcare logistics ecosystem.
Venezuela was selected as the initial target market due to increasing interest in technology-enabled healthcare infrastructure and opportunities for modernization within the country's pharmaceutical distribution sector. Management believes that continued deployment and market evaluation in Venezuela may provide a framework for expanding into additional South American markets as part of a long-term regional strategy.
The platform is designed to modernize traditional prescription fulfillment workflows through mobile-enabled prescription intake, AI-based text recognition, automated inventory verification, fulfillment coordination, and delivery routing. By addressing operational inefficiencies in underserved healthcare distribution markets across Latin America, the platform aims to improve prescription processing efficiency, reduce administrative overhead, optimize inventory coordination, and enhance customer accessibility through technology-enabled delivery systems.
Management highlighted several potential commercial advantages of the initiative, including entry into an active pharmaceutical retail environment in a major Latin American metropolitan market, real-world evaluation opportunities for the platform, potential recurring transaction-based revenue from prescription fulfillment volumes, and a scalable framework for future regional expansion throughout South America.
The pharmacy fulfillment initiative is intended to integrate with LataMed's broader digital healthcare ecosystem, which includes telehealth applications, healthcare analytics infrastructure, patient engagement technologies, and AI-assisted healthcare coordination platforms currently under development. According to the company, integrating pharmacy fulfillment into its software and online infrastructure may enhance operational scalability, improve user accessibility, support future platform interoperability, and strengthen its long-term digital healthcare strategy in Latin America.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: "We believe pharmacy fulfillment represents a natural extension of our digital healthcare infrastructure strategy. By combining AI-enabled prescription processing, logistics coordination, and pharmacy retail participation, we are continuing development of healthcare technology solutions designed to support accessibility, operational efficiency, and scalability across Latin America."
The company emphasized that the platform and related deployment activities remain subject to continued operational planning, technology integration, commercial readiness, regulatory considerations, partner implementation timelines, financing availability, and market adoption. No assurance can be provided regarding the timing of broader commercial deployment, transaction volumes, revenue generation, geographic expansion, or operational success.
LataMed AI Corp. (OTC: LMED) is a development-stage digital health and AI technology company focused on scalable telehealth infrastructure and healthcare analytics platforms for emerging markets. The company is advancing a technology-enabled healthcare ecosystem designed to support remote patient engagement, provider coordination, healthcare analytics, emergency response integration, pharmaceutical logistics, and broader digital healthcare delivery initiatives.
For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
